|
1
|
The International Agency for Research on
Cancer (IARC), ; Fletcher CDM, Chibon F and Mertens F: Pathology
and genetics of tumours of soft tissue and bone (IARC WHO
Classification of Tumours). IARC Press; Lyon: pp. 235–238. 2013
|
|
2
|
Gronchi A, Palmerini E, Quagliuolo V,
Broto JM, Pousa AL, Grignani G, Brunello A, Blay JY, Tendero O,
Beveridge RD, et al: Neoadjuvant chemotherapy in high-risk soft
tissue sarcomas: Final results of a randomized trial from Italian
(ISG), Spanish (GEIS), French (FSG), and Polish (PSG) sarcoma
groups. J Clin Oncol. 1:2178–2186. 2020. View Article : Google Scholar
|
|
3
|
Kim JH, Park HS, Heo SJ, Kim SK, Han JW,
Shin KH, Kim SH, Hur H, Kim KS, Choi YD, et al: Differences in the
efficacies of pazopanib and gemcitabine/docetaxel as second-line
treatments for metastatic soft tissue sarcoma. Oncology. 96:59–69.
2019. View Article : Google Scholar
|
|
4
|
Nakamura T, Tsukushi S, Asanuma K,
Katagiri H, Ikuta K, Nagano A, Kozawa E, Yamada S, Shido Y, Yamada
K, et al: The clinical outcome of eribulin treatment in Japanese
patients with advanced soft tissue sarcoma: A tokai musculoskeletal
oncology consortium study. Clin Exp Metastasis. 36:343–350. 2019.
View Article : Google Scholar
|
|
5
|
Schalper KA, Carvajal-Hausdorf D,
McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L,
Herbst RS and Rimm DL: Differential expression and significance of
PD-L1, IDO-1, and B7-H4 in human lung cancer. Clin Cancer Res.
15:370–378. 2017. View Article : Google Scholar
|
|
6
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 22:252–264.
2012. View
Article : Google Scholar
|
|
7
|
Syn NL, Teng MW, Mok TS and Soo RA:
De-Novo and acquired resistance to immune checkpoint targeting.
Lancet Oncol. 18:e731–e741. 2012. View Article : Google Scholar
|
|
8
|
Ready N, Hellmann MD, Awad MM, Otterson
GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M,
et al: First-Line nivolumab plus ipilimumab in advanced
non-small-cell lung cancer (CheckMate 568): Outcomes by programmed
death ligand 1 and tumor mutational burden as biomarkers. J Clin
Oncol. 20:992–1000. 2019. View Article : Google Scholar
|
|
9
|
Tawbi HA, Burgess M, Bolejack V, Van Tine
BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA,
et al: Pembrolizumab in advanced soft-tissue sarcoma and bone
sarcoma (SARC028): A multicentre, two-cohort, single-arm,
open-label, phase 2 trial. Lancet Oncol. 18:1493–1501. 2017.
View Article : Google Scholar
|
|
10
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite instability/mismatch
repair-deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 1:1–10. 2020. View Article : Google Scholar
|
|
11
|
Flores-Martin JF, Perea F, Exposito-Ruiz
M, Carretero FJ, Rodriguez T, Villamediana M, Ruiz-Cabello F,
Garrido F, Cózar-Olmo JM and Aptsiauri N: A combination of positive
tumor HLA-I and negative PD-L1 expression provides an immune
rejection mechanism in bladder cancer. Ann Surg Oncol.
26:2631–2639. 2019. View Article : Google Scholar
|
|
12
|
Johnson DB, Bordeaux J, Kim JY, Vaupel C,
Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, et al:
Quantitative spatial profiling of PD-1/PD-L1 interaction and
HLA-DR/IDO-1 predicts improved outcomes of anti-PD-1 therapies in
metastatic melanoma. Clin Cancer Res. 1:5250–5260. 2018.
|
|
13
|
Munn DH and Mellor AL: Indoleamine 2,3
dioxygenase and metabolic control of immune responses. Trends
Immunol. 34:137–143. 2013. View Article : Google Scholar
|
|
14
|
Prendergast GC, Smith C, Thomas S,
Mandik-Nayak L, Laury- Kleintop L, Metz R and Muller AJ:
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and
immune escape in cancer. Cancer Immunol Immunother. 63:721–735.
2014. View Article : Google Scholar
|
|
15
|
Long GV, Dummer R, Hamid O, Gajewski TF,
Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, et al:
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in
patients with unresectable or metastatic melanoma
(ECHO-301/KEYNOTE-252): A phase 3, randomised, double-blind study.
Lancet Oncol. 20:1083–1097. 2019. View Article : Google Scholar
|
|
16
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 27:568–571. 2014. View Article : Google Scholar
|
|
17
|
Sznol M and Chen L: Antagonist antibodies
to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human
cancer. Clin Cancer Res. 19:1021–1034. 2013. View Article : Google Scholar
|
|
18
|
Yoshimoto M, Yamada Y, Ishihara S, Kohashi
K, Toda Y, Ito Y, Yamamoto H, Furue M, Nakashima Y and Oda Y:
Comparative study of myxofibrosarcoma with undifferentiated
pleomorphic sarcoma: Histopathologic and clinicopathologic review.
Am J Surg Pathol. 44:87–97. 2020. View Article : Google Scholar
|
|
19
|
Thway K, Flora R, Shah C, Olmos D and
Fisher C: Diagnostic utility of p16, CDK4, and MDM2 as an
immunohistochemical panel in distinguishing well-differentiated and
dedifferentiated liposarcomas from other adipocytic tumors. Am J
Surg Pathol. 36:462–469. 2012. View Article : Google Scholar
|
|
20
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition.
Springer; St. Louis, MO: 2010
|
|
21
|
Volaric A, Gentzler R, Hall R, Mehaffey
JH, Stelow EB, Bullock TN, Martin LW and Mills AM:
Indoleamine-2,3-dioxygenase in non-small cell lung cancer: A
targetable mechanism of immune resistance frequently coexpressed
with PD-L1. Am J Surg Pathol. 42:1216–1223. 2018. View Article : Google Scholar
|
|
22
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 9:1540–1550. 2016.
View Article : Google Scholar
|
|
23
|
Reck M, Rodriguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 10:1823–1833. 2016.
View Article : Google Scholar
|
|
24
|
Seeber A, Klinglmair G, Fritz J, Steinkohl
F, Zimmer KC, Aigner F, Horninger W, Gastl G, Zelger B, Brunner A
and Pichler R: High IDO-1 expression in tumor endothelial cells is
associated with response to immunotherapy in metastatic renal cell
carcinoma. Cancer Sci. 109:1583–1591. 2018. View Article : Google Scholar
|
|
25
|
Perea F, Bernal M, Sánchez-Palencia A,
Carretero J, Torres C, Bayarri C, Gómez-Morales M, Garrido F and
Ruiz-Cabello F: The absence of HLA class I expression in non-small
cell lung cancer correlates with the tumor tissue structure and the
pattern of T cell infiltration. Int J Cancer. 15:888–899. 2017.
View Article : Google Scholar
|
|
26
|
Nakano K, Yamamoto H, Fujiwara M, Koga Y,
Tsuruta S, Ihara E, Oki E, Nakamura M, Ogawa Y and Oda Y:
Clinicopathologic and molecular characteristics of synchronous
colorectal carcinoma with mismatch repair deficiency. Am J Surg
Pathol. 42:172–182. 2018. View Article : Google Scholar
|
|
27
|
Yoo SH, Keam B, Ock CY, Kim S, Han B, Kim
JW, Lee KW, Jeon YK, Jung KC, Chung EJ, et al: Prognostic value of
the association between MHC class I downregulation and PD-L1
upregulation in head and neck squamous cell carcinoma patients. Sci
Rep. 22:76802019. View Article : Google Scholar
|
|
28
|
Hakozaki M, Hojo H, Sato M, Tajino T,
Yamada H, Kikuchi S and Abe M: Establishment and characterization
of a new cell line, FPS-1, derived from human undifferentiated
pleomorphic sarcoma, overexpressing epidermal growth factor
receptor and cyclooxygenase-2. Anticancer Res. 26:3393–3401.
2006.
|
|
29
|
Nishio J, Iwasaki H, Nabeshima K, Ishiguro
M, Isayama T and Naito M: Establishment of a new human pleomorphic
malignant fibrous histiocytoma cell line, FU-MFH-2: Molecular
cytogenetic characterization by multicolor fluorescence in situ
hybridization and comparative genomic hybridization. J Exp Clin
Cancer Res. 24:1532010. View Article : Google Scholar
|
|
30
|
Boxberg M, Steiger K, Lenze U, Rechl H,
von Eisenhart-Rothe R, Wörtler K, Weichert W, Langer R and Specht
K: PD-L1 and PD-1 and characterization of tumor-infiltrating
lymphocytes in high grade sarcomas of soft tissue-prognostic
implications and rationale for immunotherapy. Oncoimmunology.
20:e13893662017.
|
|
31
|
Burr ML, Sparbier CE, Chan YC, Williamson
JC, Woods K, Beavis PA, Lam EY, Henderson MA, Bell CC, Stolzenburg
S, et al: CMTM6 maintains the expression of PD-L1 and regulates
anti-tumour immunity. Nature. 7:101–105. 2017. View Article : Google Scholar
|
|
32
|
Sun R, Limkin EJ, Vakalopoulou M, Dercle
L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S,
et al: A radiomics approach to assess tumour-infiltrating CD8 cells
and response to anti-PD-1 or anti-PD-L1 immunotherapy: An imaging
biomarker, retrospective multicohort study. Lancet Oncol.
19:1180–1191. 2018. View Article : Google Scholar
|
|
33
|
Patil PA, Blakely AM, Lombardo KA, Machan
JT, Miner TJ, Wang LJ, Marwaha AS and Matoso A: Expression of
PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment
in gastric adenocarcinoma. Histopathology. 73:124–136. 2018.
View Article : Google Scholar
|
|
34
|
Zheng C, You W, Wan P, Jiang X, Chen J,
Zheng Y, Li W, Tan J and Zhang S: Clinicopathological and
prognostic significance of PD-L1 expression in sarcoma: A
systematic review and meta-analysis. Medicine (Baltimore).
97:e110042018. View Article : Google Scholar
|
|
35
|
Vasileios KA, Eward WC and Brigman BE:
Surgical treatment and prognosis in patients with high-grade soft
tissue malignant fibrous histiocytoma of the extremities. Arch
Orthop Trauma Surg. 132:955–961. 2012. View Article : Google Scholar
|
|
36
|
Roland CL, May CD, Watson KL, Al Sannaa
GA, Dineen SP, Feig R, Landers S, Ingram DR, Wang WL, Guadagnolo
BA, et al: Analysis of clinical and molecular factors impacting
oncologic outcomes in undifferentiated pleomorphic sarcoma. Ann
Surg Oncol. 23:2220–2228. 2016. View Article : Google Scholar
|
